Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.

A recent study that focused on women under 55 years old found an increase in pancreatic cancer cases.Mercy Medical Center Dr.

Liver cancer is a leading cause of cancer-related deaths worldwide, with distinct geographic patterns in its incidence. In particular, China bears a disproportionate share of the global burden. The ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron, is ...